Century Therapeutics (NASDAQ:IPSC) Stock Moved Down to Sell by Wall Street Zen

Wall Street Zen cut shares of Century Therapeutics (NASDAQ:IPSC) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a research note on Tuesday, September 29th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Century Therapeutics has a consensus rating of “Hold” and an average price target of $4.75.

Century Therapeutics Stock Up 2.0%

Shares of IPSC stock opened at $1.49 on Friday. Century Therapeutics has a 12 month low of $0.43 and a 12 month high of $3.04. The company’s fifty day simple moving average is $1.74 and its 200-day simple moving average is $2.09. The firm has a market cap of $269.61 million, a PE ratio of -1.60 and a beta of 1.67.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). On average, equities analysts predict that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IPSC. Quadrant Private Wealth Management LLC grew its position in shares of Century Therapeutics by 31.0% in the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock valued at $45,000 after purchasing an additional 4,736 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Century Therapeutics during the 1st quarter worth approximately $29,000. State of Wyoming bought a new stake in Century Therapeutics in the 2nd quarter valued at $82,000. The Manufacturers Life Insurance Company bought a new stake in Century Therapeutics in the 2nd quarter valued at $85,000. Finally, Legal & General Group Plc bought a new stake in Century Therapeutics in the 2nd quarter valued at $108,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.

Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.